Loading…
Quoin Pharmaceuticals Ltd.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -100.0% over 5Y.
today you would have $0.07▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $14.43 | $22.78 | $171.68 | $596.40 | |
| P/B | 31.2x | 57.7x | 22.2x | 29.9x | 32.5x |
| EPS | -$14.80 | -$66.85 | -$337.47 | -$1,638.23 | |
| ROE | -123.56% | -120.46% | -97.37% | -153.36% | -126.66% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| IRIXIridex Corp | $0.71 | — | — | — | -73.15% | $12.3M |
| HCTIHealthcare Triangle, Inc. | $0.84 | — | 0.1x | — | -57.41% | $12.36M |
| ASBPAspire Biopharma Holdings, Inc. | $8.51 | — | 0.9x | — | -1032.14% | $11.94M |
| MBRXMoleculin Biotech, Inc. | $0.65 |
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Company description provided by Yahoo Finance.
| 0.0x |
| 0.4x |
| — |
| -1371.64% |
| $12.66M |
| PDSBPDS Biotechnology Corp | $0.21 | — | — | — | -543.97% | $11.8M |
| SNTISenti Biosciences Holdings, Inc. | $0.38 | — | 4.6x | — | -466.46% | $11.74M |